Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Theratechnologies Inc (NQ: THTX ) 1.230 -0.050 (-3.91%) Streaming Delayed Price Updated: 2:23 PM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Theratechnologies Inc < Previous 1 2 3 Next > Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 July 10, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update June 26, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors May 23, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Reports on its Annual Meeting of Shareholders May 09, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting May 02, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders April 15, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 11, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 April 10, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform April 08, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Appoints Elina Tea to its Board of Directors April 05, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update April 03, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform March 28, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Announces Update on its Preclinical Oncology Research Program March 22, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Appoints Jordan Zwick to its Board of Directors March 21, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer March 21, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau February 29, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA February 27, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance February 21, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action February 20, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer February 15, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update February 06, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA January 24, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application January 23, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA January 02, 2024 From Theratechnologies Via GlobeNewswire Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose December 13, 2023 From Theratechnologies Via GlobeNewswire Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award November 24, 2023 Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer From Theratechnologies Via GlobeNewswire Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement October 31, 2023 From Theratechnologies Via GlobeNewswire Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement October 26, 2023 From Theratechnologies Via GlobeNewswire Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement October 25, 2023 From Theratechnologies Via GlobeNewswire Theratechnologies Announces Operational Update October 24, 2023 From Theratechnologies Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
